Monograph
A01AD01 - Epinephrine |
Not porphyrinogenic |
NP |
Rationale
Epinephrine (adrenaline) is an endogenous catecholamine with non-CYP dependent metabolism. There are no data pointing to CYP-interaction.
Chemical description
Endogenous catecholamine.
Therapeutic characteristics
Epinephrine (adrenaline) is a catecholamine used in asthma bronchiale, cardiac arrest, hypersensitivity reactions. Parenterally administered in 0.3-1 mg dose.
Metabolism and pharmacokinetics
Epinephrine (adrenalin) is an endogenous compound. It is very rapidly inactivated by processes which include uptake into adrenergic neurones, diffusion, and enzymatic degradation in the liver and body tissues. Metabolism involves monoamine oxidase (MAO) and catechol-O-methyl transferase (COMT). As a result of enzymatic degradation in the gut and first-pass metabolism in the liver, adrenaline is almost totally inactive when given orally.
IPNet drug reports
Uneventful use reported in 5 patients with acute porphyria, in combination with local anaesthetics.
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | MFM James, RJ Hift. Porphyrias. Br J Anaesth 2000; 85, 143-53.
|
|
| * | Drug reference publications | |
| 2. | Sweetman SC, editor. Martindale: The complete drug reference. Adrenaline. Pharmaceutical Press 2009.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Norway© NAPOS 2024